POU4F2 and breast cancer: Thus, Brn-3b promoter activity can be inhibited by blocking the MAPK/extracellular signal-regulated kinase (ERK) pathway by using either pharmacological inhibitors or dnMEK, thereby identifying the MAPK/ERK pathway as a pivotal regulator of Brn-3b expression in breast cancer cells.